Sign In
Buy MBRX
$2.46
+0 (+0%)
At Close: Jun 03, 2026
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistica
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
08:30am, Thursday, 17'th Apr 2025
HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidate
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
11:01am, Tuesday, 01'st Apr 2025
Moleculin Biotech (MBRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
08:30am, Tuesday, 01'st Apr 2025
– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharm
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
01:00pm, Wednesday, 26'th Mar 2025
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript
10:50am, Monday, 24'th Mar 2025
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO John Paul Waymack - Senior CMO Jonathan Foster -
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
07:05am, Monday, 24'th Mar 2025
– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
08:05am, Wednesday, 19'th Mar 2025
HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidate
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
08:45am, Tuesday, 11'th Mar 2025
On-demand video webcast now available here HOUSTON , March 11, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a b
Moleculin to Present at the 37th Annual ROTH Conference
08:45am, Monday, 10'th Mar 2025
Live webcast fireside chat on Tuesday, March 18 th at 11:00 AM PT HOUSTON , March 10, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmace
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
08:30am, Thursday, 06'th Mar 2025
New patents will extend coverage to major markets outside the U.S., expanding upon existing U.S. claims Affirms expectations for an initial data readout of the phase 3 MIRACLE trial for the second hal
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
08:30am, Monday, 03'rd Mar 2025
HOUSTON , March 3, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting
HOUSTON , Feb. 25, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting
Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?
01:19pm, Thursday, 13'th Feb 2025
On Thursday, Moleculin Biotech, Inc., MBRX stock is surging with a strong session volume of 64.85 million compared to an average volume of 157.048K, as per data from Benzinga Pro.
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
01:05pm, Thursday, 13'th Feb 2025
HOUSTON , Feb. 13, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting
